Importance The most common leukemia is chronic lymphocytic leukemia (CLL). Every year,
there are 15 000 new diagnoses and 5000 CLL deaths in the United States. Although …

Background Auger electron emitters that can be targeted into DNA of tumour cells represent
an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the …

Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52,
resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple …

Chronic lymphocytic leukaemia (CLL) is a malignant haematological disorder that remains
mostly incurable; more than 95% of patients have disease of B-cell origin. Advances with …

The effect of CMC‐544, a calicheamicin‐conjugated anti‐CD22 monoclonal antibody, was
analysed in relation to CD22 and P‐glycoprotein (P‐gp) in B‐cell chronic lymphocytic …

Anti-tumor monoclonal antibody therapy represents one of the earliest targeted therapy in
clinical cancer care and has achieved a great clinical promise. Complement activation …

Alemtuzumab has been used in off-label studies of solid organ transplantation. We extend
our report of the first 200 consecutive living donor solitary kidney transplantations under …

Background. Alemtuzumab has been used in off-label studies of solid organ transplantation.
Methods. We analyzed the first 42 pediatric consecutive living donor kidney transplantations …

The recent success of monoclonal antibodies in the treatment of various hematological and
nonhematological cancers is the result of several decades of research in immune therapy of …

Direct contact with stromal cells protects chronic lymphocytic leukaemia (CLL) B cells from
chemotherapy‐induced apoptosis in vitro. Blockade of CXCR4 signalling antagonizes …